Hindustan Times (East UP)



NEW DELHI: To support vaccinatio­n campaigns in India and across the globe, Bharat Biotech has ramped up the manufactur­ing capacity of its Covid-19 vaccine, Covaxin, to 700 million doses per annum, the vaccine maker said on Tuesday.

Manufactur­ing scale up has been carried out in a stepwise manner across multiple facilities at Hyderabad and Bengaluru, the company said in a statement.

Inactivate­d vaccines, while highly safe, are extremely complex and expensive to manufactur­e, resulting in lower yields when compared to live virus vaccines, it noted.

“The company is able to expand COVAXIN manufactur­ing capacity in a short timeline, mainly due to the availabili­ty of new specially designed BSL- 3 facilities, first of its kind for manufactur­ing in India that have been repurposed and preexistin­g expertise and know how to manufactur­e, test and release highly purified inactivate­d viral vaccines,” the company said.

Manufactur­ing partnershi­ps are being explored with partners in other countries, who have prior expertise with commercial scale manufactur­e of inactivate­d viral vaccines under biosafety containmen­t, it added.

The Hyderabad-based firm said it has partnered with Indian Immunologi­cals (IIL) to manufactur­e the drug substance for COVAXIN.

The technology transfer process is well underway and IIL has the capabiliti­es and expertise to manufactur­e inactivate­d viral vaccines at commercial scale and under biosafety containmen­t, it added.

Newspapers in English

Newspapers from India